Nissan Halts Electric Qashqai Development Amid EV Market Challenges 
Apollo Debt Solutions Limits Redemptions as Withdrawal Requests Surge 
Baseten Secures $1.5 Billion Funding at $13 Billion Valuation Amid AI Infrastructure Boom 
NTSB Investigates Boston Logan Airport Near-Miss Between Delta and American Airlines Jets 
Meta Pauses Employee Activity Tracking Program Over Data Security Concerns 
SK Hynix Overtakes Samsung as South Korea’s Most Valuable Company 
NHTSA Investigates Fatal Tesla Model 3 Crash in Texas Amid Ongoing Autopilot and FSD Safety Scrutiny 
J.P. Morgan Sees Potential Vestas Guidance Upgrade Amid Strong Wind Energy Demand 
California Drivers Sue BP, Walmart, 7-Eleven Over Alleged AI Gas Price Fixing 
JPMorgan Sees Strong Strategic Value in Potential AbbVie Acquisition of Apogee Therapeutics 
Google’s Open-Source AI Data Center Cooling Design Raises Commoditization Concerns 
SpaceX Stock Plunges 16% as KeyBanc Warns Valuation May Be Overstretched 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Alphabet Stock Slides as AI Talent Exodus and SpaceX Losses Shake Investor Confidence 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Trump’s Quantum Push Lifts IBM Stock as CEO Arvind Krishna Receives White House Praise 
Samsung Bioepis Co. Ltd.'s commercial partner Organon will supply its Hadlima autoimmune disease treatment to the United States after winning an order from the U.S. Department of Veterans Affairs. It was agreed that U.S.-based Organon would deliver the biosimilar Hadlima drugs for five years.
Organon will now deliver Hadlima biosimilar treatment to the Department of Veterans Affairs (V.A.). This well-known drug is mainly used for medicating rheumatoid arthritis, spondyloarthritis, and psoriasis. According to The Korea Economic Daily, AbbVie Inc., a pharmaceutical company headquartered in North Chicago, Illinois, developed the original drug.
Orders from the U.S.
The latest order was revealed by Organon, the partner company of Samsung Bioepis based in the U.S. On Wednesday, Feb. 21, the firm said that Organon won a bidding contract to supply Hadlima to the American government agency. Consequently, Organon will supply Hadlima to hospitals under the Ministry of Veterans Affairs for the next five years.
The Veterans Affairs
The VA is a government agency for veterans in the United States. It provides benefits in various fields, such as medical care and finance, and is building a general hospital-level hospital network and medical infrastructure throughout the United States.
"America's veterans deserve access to quality medicines at a lower cost. We are proud to support the more than nine million people enrolled in the VA healthcare system through this collaboration, which is a great example of industry and public sector working together," Kevin Ali, Organon CEO, said in a press release. "We applaud the VA for its leadership in championing biosimilars and including all three of Organon's biosimilars available in the US on its formulary."
Photo by: Organon Media
